Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 24;61(5):e02418-16.
doi: 10.1128/AAC.02418-16. Print 2017 May.

Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis

Affiliations

Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis

C Garcia-de-la-Maria et al. Antimicrob Agents Chemother. .

Abstract

Among the viridans group streptococci, the Streptococcus mitis group is the most common cause of infective endocarditis. These bacteria have a propensity to be β-lactam resistant, as well as to rapidly develop high-level and durable resistance to daptomycin (DAP). We compared a parental, daptomycin-susceptible (DAPs) S. mitis/S. oralis strain and its daptomycin-resistant (DAPr) variant in a model of experimental endocarditis in terms of (i) their relative fitness in multiple target organs in this model (vegetations, kidneys, spleen) when animals were challenged individually and in a coinfection strategy and (ii) their survivability during therapy with daptomycin-gentamicin (an in vitro combination synergistic against the parental strain). The DAPr variant was initially isolated from the cardiac vegetations of animals with experimental endocarditis caused by the parental DAPs strain following treatment with daptomycin. The parental strain and the DAPr variant were comparably virulent when animals were individually challenged. In contrast, in the coinfection model without daptomycin therapy, at both the 106- and 107-CFU/ml challenge inocula, the parental strain outcompeted the DAPr variant in all target organs, especially the kidneys and spleen. When the animals in the coinfection model of endocarditis were treated with DAP-gentamicin, the DAPs strain was completely eliminated, while the DAPr variant persisted in all target tissues. These data underscore that the acquisition of DAPr in S. mitis/S. oralis does come at an intrinsic fitness cost, although this resistance phenotype is completely protective against therapy with a potentially synergistic DAP regimen.

Keywords: Streptococcus mitis group; daptomycin; experimental endocarditis; fitness; gentamicin; high-level daptomycin resistance; virulence.

PubMed Disclaimer

Figures

FIG 1
FIG 1
(A) Results of time-kill experiments for DAPs strain S.MIT/ORALIS-351 incubated with DAP plus GEN at concentrations of 0.5× MIC and 1× MIC for both antibiotics. (B) Results of time-kill experiments for the DAPr variant incubated with DAP plus GEN at concentrations of 64 μg/ml and 128 μg/ml for DAP and 4 μg/ml and 8 μg/ml for GEN. The numbers in the keys are concentrations (in micrograms per milliliter).

Similar articles

Cited by

References

    1. Fowler VG, Scheld WM, Bayer AS. 2015. Endocarditis and intravascular infections, p 990–1028. In Principles and practices of infectious diseases. Elsevier Inc, Amsterdam, The Netherlands.
    1. Shelburne SA, Sahasrabhojane P, Saldana M, Yao H, Su X, Horstmann N, Thompson E, Flores AR. 2014. Streptococcus mitis strains causing severe clinical disease in cancer patients. Emerg Infect Dis 20:762–771. doi:10.3201/eid2005.130953. - DOI - PMC - PubMed
    1. Freifeld AG, Razonable RR. 2014. Viridans group streptococci in febrile neutropenic cancer patients: what should we fear? Clin Infect Dis 59:231–233. doi:10.1093/cid/ciu264. - DOI - PubMed
    1. Shelburne SA, Lasky RE, Sahasrabhojane P, Tarrand JT, Rolston KV. 2014. Development and validation of a clinical model to predict the presence of β-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients. Clin Infect Dis 59:223–230. doi:10.1093/cid/ciu260. - DOI - PubMed
    1. Ahmed R, Hassall T, Morland B, Gray J. 2003. Viridans streptococcus bacteremia in children on chemotherapy for cancer: an underestimated problem. Pediatr Hematol Oncol 20:439–444. - PubMed

Publication types

MeSH terms